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The reassessment of technologies and services offered by healthcare systems is recent ini-
tiative and still without a widely adopted and evaluated method. To a better understanding of
this process in Brazil, we have described the health technology reassessment (HTR) per-
formed by the National Committee for Health Technology Incorporation (Conitec) into Brazil-
ian public health system (SUS).
Methods
A documental, exploratory, descriptive, retrospective study with qualitative-quantitative
approach regarding the HTR performed by Conitec from January 2012 to November 2017.
Results
After applying the criteria of inclusion and exclusion, we selected 47 technologies for this
study. The vast majority of the demands (41 demands) came from the public sector, and
only six from the private sector. Most of the requests referred to the exclusion of specific
indication; followed by extension of use, withdraw of the technology from SUS, mainte-
nance, and restriction of use. The dimensions of analysis found in the recommendation
reports were scientific evidence on efficacy, effectiveness and safety, disease-related
issues, issues related to the use of technology, costs, and social participation. However,
these dimensions were not included in all analysis, and a standardized structure of the
reports has not been observed. The most relevant decision factors considered for decision-
making were efficacy, safety and use of the technology.
Conclusion
During a six-year period of Conitec actuation, we could find some reassessments of technol-
ogies that are available in SUS. We observed that these activities had enabled progress,
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however, they are still not yet structured, with gaps in the selection process, and the assess-
ment since no methodology and criteria for proper conduct were established.
Introduction
The process of Health Technology Assessment (HTA) considers primarily the results of effi-
cacy studies, mostly from randomized clinical studies. However, despite being essentials, these
studies often point out a high degree of uncertainty to the real benefits to the population,
which, in many cases, is not proportional to the resources invested [1,2]. This phenomenon is
easily observed, for example, in new technologies for oncological treatments, which costs are
incredibly high and the benefits are marginal [3].
According to the Brazilian Institute of Geography and Statistics (IBGE), between 2013 and
2014, the final consumption of health goods and services rose from 8.2% to 8.7% of Gross
Domestic Product (GDP). In 2015, the health expenditures were R$ 546 billion (9.1% of GDP),
with 79.2% of health services and 19% of medicines. The rest referred to the consumption of
other medical, ophthalmological, and dental materials. Considering these data, approximately
one-fifth of health expenditures is related to the use of medicinal drugs, only surpassed by hos-
pital cost, outpatient and preventive services and sanitary surveillance [4].
It is essential to define tools that can support decision-makers in the adoption and re-evalu-
ation of technologies within health systems. Among many reasons for this approach, we can
cite the prospects for an increase in the use of drugs and other health technologies to meet the
demands of a population that are progressively expanding associated with an increase in the
prevalence of chronic degenerative diseases, together with the highly complex and contextual-
ized analysis for selection of technologies and services.
Regarding the adoption of new technologies, there has been much effort in the study of
methods used by Health Technology Assessment (HTA) agencies and how to improve them,
so that this process can apprehend all the relevant aspects of the intervention in a given con-
text. Consequently, more objective and transparent methodologies and criteria that take into
account the perspectives of different stakeholders have been developed and validated in several
countries to optimize the allocation of resources and contribute to more consistent decisions
before society [5–7].
On the other hand, studies on reassessment methodologies to monitor and evaluate the use
of technologies are less frequent and have only recently become available; more precisely, since
2006 [8]. The health policy forum of the HTAi (Health Technology Assessment International)
of 2012 proposed that health reassessment of technology (HTR) become an HTA standardized
practice. HTR is defined as "a structured, evidence-based assessment of the clinical, social, ethi-
cal, and economic effects of a technology currently used in the healthcare system, to inform
optimal use of that technology in comparison to its alternatives" [9].
Such a process is fundamental to the quality of care offered to the patient and the sustain-
ability of the health system, as resources could be reinvested in more useful or less expensive
health services. Within the technology lifecycle, this phase aims at finding technologies that
present inferior results to those that subsidize their adoption or even interventions that are
ineffective or harmful to the patient or the health service [10]. Hence, the HTR, recommenda-
tions such as maintenance, total disinvestment, partial disinvestment (restriction of the user
group), extension of use, reduction of quantity and price can be adopted [11].
Some studies were conducted targeting low-value practices, which, according to Colla and
colleagues, are "the use of care that is unlikely to benefit the patient given the cost, available
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alternatives, and preferences of the patient" [10]. Prasad and colleagues evaluated 363 studies
on established health interventions and observed that 138 practices (38.0%) confirmed their
efficacy, 79 (21.8%) presented inconclusive data and 146 (40.2%) were ineffective [11].
In another review, Niven and colleagues have reported cardiovascular diseases, arthritis,
and menopause as the most common target conditions in de-adoption studies–discontinua-
tion of current clinical practice. The most researched therapies were cyclooxygenase-2 inhibi-
tors (COX-2) and other non-steroidal anti-inflammatory drugs (NSAIDs), hormone
replacement therapy and percutaneous coronary intervention [12].
Considering that the low-value practices are a potential waste and can be harmful to the
patient’s health, some countries (e.g.: France, England, Australia, Spain, Canada, and the
United Kingdom) have already begun monitoring the technology after a certain period past its
implementation in the health care system [13–16].
During the French health system reform, there was a review of the complete list of reim-
bursed drugs and those considered ineffective were withdrawn from the health system. In
addition to this strategy, there were also others like greater access to average European prices
for innovative drugs, stimulation of discounts for over-prescription drugs and programs to
increase the prescription of generic medicines. The result of HTR and the further decision not
to reimburse the ineffective medications represented an estimated savings of 450 million
euros/year, in addition to the savings generated by the implementation of the other reform ini-
tiatives (1.7 billion euros / year—period from 2003 to 2007) [13].
These data about the French health system emphasize that combining several strategies to
improve technologies management, results in a significant impact on economic resources.
However, the sustainability of health systems involves other aspects beyond the financials ones
(structural analysis); such as the continuity of the provided services (organizational analysis)
and the obtained benefits (individual analysis) [17]. These aspects must be audited and
assessed continuously to ensure waste reduction, without compromising the health benefits
already gained, plus helping to foster improvements.
In Brazil, the National Committee for Health Technology Incorporation (Conitec) was
established in 2011 to improve the decision-making process in HTA. The primary purpose of
this committee is advising the Ministry of Health on decisions related to the adoption, disin-
vestment or changes in the use of health technologies in SUS, as well as the development or
update of clinical protocols or therapeutic guidelines [18]. Conitec chief responsibility is to
issue a recommendation based on efficacy, accuracy, effectiveness, and safety of the technol-
ogy, comparative economic evaluation of the benefits and costs concerning the technologies
already available in SUS and budget impact. However, to issue the final decision is the duty of
the Secretary of Science, Technology and Strategic Inputs of the Ministry of Health [18,19].
Conitec creation has promoted advances in the institutionalization of HTA in the Brazilian
health system, due to the rationality and use of clinical and economic evidence in decisions
about the inclusion of new technologies in SUS. Some studies on the work of the Committee
have been published with the purpose of outlining the evaluation process, the demands, and
the recommendations about the adoption of technologies [10–12]. However, such studies ana-
lyzed the set of evaluations and recommendations, without highlighting the specific character-
istics of the HTR process used by Conitec.
Therefore, the present study aimed to analyze and characterize the process of HTR carried
out by Conitec, focusing on the dimensions of analysis, criteria and decision factors that were
relevant for the Committee recommendations.
This study is the first step of our project. The full project consists of 5 steps: 1- Review of
the current state of HTR carried out by Conitec; 2- Systematic review of the literature; 3-
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Development of a RTS framework; 4- Pilot study using the RTS framework; 5- Evaluation of
the results, adjustments and validation of the RTS framework.
Materials and methods
We carried out a documental, exploratory, descriptive, retrospective study with qualitative-
quantitative approach regarding the HTR performed by Conitec from January 2012 to Novem-
ber 2017.
The study comprised the following steps:




Description of the HTR process and Conitec recommendations from the analysis of (i) consis-
tency in the report on presenting analysis of dimension and criteria as evidence, issues related
to the context of disease and technology, costs, public consultation, and others–and (ii) the
decision factors for Conitec recommendations.
Classification and selection of technologies
Most of the final decisions were issued as “adoption” or “no adoption” of technology, regard-
less of the technology is already available in n SUS. Thus, for selecting the reassessed technolo-
gies, the types of evaluation requests, and so the final decisions, were reclassified based on the
availability of the technology in SUS for the assessed indications, as shown in the Table 1.
Inclusion criteria. All technologies available in SUS, and that were reassessed for an indi-
cation already approved within the health system.
• Health technologies: drugs, vaccines, health devices, and procedures.
• Reassessed technologies: health technologies (already) available in SUS, assessed in the same
presentation and for the same indication.
The reassessment request/decision was an extension of use/not extension of use (items b.2,
b.3, b.4); maintenance/delisting from SUS (items c and f), restriction of use (item d); mainte-
nance/exclusion of indication (item e).
Exclusion criteria. The exclusion criteria were as follows:
• Clinical protocols and therapeutic guidelines were not included. Each inclusion, exclusion,
and change of use of technologies when drawing up or revising the protocols go through the
same process of evaluation of other technologies and are contained in the set of technologies
evaluated [20].
• New health technologies (in SUS context): technologies that were not available in SUS dur-
ing the assessment period.
• Drugs with new concentration, new pharmaceutical form and new route of administration
were also considered as new technologies for the health system, and, therefore, excluded
from the present study.
• Technologies with a new indication, although already available in the health system for other
clinical situations.
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Search and data extraction methods
The public data were collected directly from the recommendation reports available on the
Committee website (January 2012 until November 2017) [21], namely:
i. Technology name;
ii. Amount of technologies by decision: the analysis unit was defined as being the reassessed
technology, even in cases where the demand or decision was related to more than one
technology;
iii. Type of technology: drug, vaccine, device, procedure;
iv. Type of applicant: public sector (Ministry of Health and related institutions, State and
Municipal Health Secretariats, Judicial Power) and private sector (pharmaceutical labora-
tories, nonprofit organizations as patient associations, medical organizations/associations);
v. Indication;
vi. Type of assessment (reclassification as described in the method): new technology, new pre-
sentation, extension of use (new indication), extension of use (a change in the therapeutic
line, wide age range, increase in the treatment period), maintenance, restriction of use,
exclusion of indication, delisting, exclusion of the International Classification of Diseases
(ICD) from the protocol, protocol/guideline approval;
vii. Dimensions of analysis and criteria in the recommendation report;
viii. Decision factors for the recommendation; and
ix. Final decision.
Table 1. Definition of the types of request/decision to classify the technologies evaluated by Conitec.
Types of request Definition
a) Adoption of new health technologies a.1) Technology is not available in SUS during the assessment
period.
a.2) New concentration, new pharmaceutical form and new route
of administration: presentation not available in SUS during the
assessment period.
b) Extension of use b.1) New indication: extension of use for an indication different
from those already approved for use within the SUS.
b.2) Change in treatment line (e.g., request to change the drug
indication from 2nd line to 1st line);
b.3) Widening in the age range;
b.4) Increase in the period of treatment: increase in the use of
technology for the same indication for which it was already
available in the SUS.
c) Maintenance Maintenance of the technology for the same indication for which
it was already available in SUS.
d) Restriction of use Restriction of the group of patients using the technology.
e) Exclusion of indication Exclusion of specific indication for the use of technology but
maintaining its use for the other indications approved within the
SUS.
f) Exclusion from SUS (Delisting) Exclusion of technology from SUS.
g) Exclusion of the International Classification
of Diseases (ICD) from the protocol
Exclusion of specific indication from the therapeutic protocol.
h) Protocols/Guidelines approval Approval of update or new Clinical Protocol and Therapeutic
Guideline.
https://doi.org/10.1371/journal.pone.0220131.t001
Health technology reassessment in the Brazilian public health system
PLOS ONE | https://doi.org/10.1371/journal.pone.0220131 July 29, 2019 5 / 18
The data related to the dimensions of analysis and criteria were extracted considering the
main items in recommendation reports. The data related to the decision factors were collected
from the items “final considerations” and “final recommendation” when the reports presented
them. For reports that did not have a standardized structure, the above information was
extracted from the full reading of the reports.
Data analysis
Statistical analysis was performed using the frequency of the dimensions of analysis, criteria
and decision factors presented in the recommendation reports. Then the findings were orga-
nized in tables with narrative description and discussion.
Results
Description of HTA requested to Conitec
Conitec had assessed 333 technologies, which includes drugs, vaccines, devices, procedures,
and clinical protocols from January 2012 until November 2017 (S1 Table). Among of them,
the vast majority was related to the adoption of new technologies (55.8%), followed by analysis
of new indications for technologies already offered by the health system (19%) and approval of
clinical protocols (11%). Other requests accounted for 14.2% (Fig 1) of the demands.
After applying the inclusion and disinvestment criteria described in the method, 47 health
technologies were selected (14.1%), whose requests/decisions referred to a reassessment (Fig 1).
Among the 47 technologies included in the study, 44 (93.6%) were drugs, two (4.2%) proce-
dures and one vaccine (2.1%). Regarding the type of claimant, 41 (87%) demands originated
from the public sector and only six (12.8%) from the private sector. The public demands–from
the Ministry of Health and affiliated institutions–related to the extension, restriction, mainte-
nance of use, exclusion of indication or complete delisting from SUS. All these public requests
had a favorable recommendation, except the demand for widening the age range for mam-
mography as a breast cancer screening method, which the judgment was unfavorable. All the
Fig 1. Flow diagram through the phases of selection of the technologies reassessed by Conitec.
https://doi.org/10.1371/journal.pone.0220131.g001
Health technology reassessment in the Brazilian public health system
PLOS ONE | https://doi.org/10.1371/journal.pone.0220131 July 29, 2019 6 / 18
private demands from pharmaceutical laboratories were to increase the use of the medication;
three of them had received a favorable decision and three, unfavorable.
Regarding the reason of the requests, the exclusion of some specific indication (n = 19;
40.4%) was the most mentioned reason. In such cases, the technologies remained in the health
system for the previously approved use. Fourteen requirements (29.8%) were made to the
extension of the use of a given technology, twelve (25.5%) to delisting from SUS and mainte-
nance and restriction, a request each (2.1%).
Rheumatoid arthritis, HIV/AIDS, and hepatitis C were the indications for which most of
the technologies were reassessed with seventeen (36.2%), ten (21.2%) and six (12.8%) demand,
respectively. The other indications were Crohn’s disease (two), multiple sclerosis (two), hepati-
tis B (two), breast cancer (one) epidermoid carcinoma (one), cystic fibrosis and exocrine pan-
creatic disease (one), Gaucher disease (one), hepatitis A (one), malaria (one) and congenital
syphilis (one).
Dimensions of analysis in Conitec recommendation reports
The dimensions of analysis and the criteria for organizing the results were defined based on
the information collected. Then, the data were structured according to the dimensions pre-
sented in the reports: context regarding the disease and technology, scientific evidence, costs,
and social participation (Tables 2 and 3).
A little more than half of the evaluations (n = 26; 55.3%) addressed aspects related to the
disease, like its evolution, epidemiological data, diagnosis and treatment offered by the health
system. The amount of technology used within the public system was taken into consideration
in eight cases (17%). Issues concerning the implementation of technology as the availability of
the technology in the Brazilian market, drug thermolability, storage and logistics for distribu-
tion and changes on the indications approved by the National Agency of Sanitary Surveil-
lance–ANVISA were considered only in a few analyses (n = 6; 12.7%).
Clinical protocol development or updating had subsidized decisions on 22 technologies
(46.8%), all relative to the exclusion of specific technology indication or delisting from SUS.
International documents as reports of HTA and clinical protocols had based decisions on an
extension of use (change in the treatment line or wide age range) of six technologies (12.8%).
Scientific evidence about efficacy, effectiveness or safety were presented in 26 technologies
assessment (55.3%). All the reports without scientific evidence were related to decisions of
exclusion of the technology from SUS or exclusion of specific indication for a technology. The
justifications for these cases were as follows: adjustments in the clinical protocol (14 technolo-
gies) with wrong recommendations (drugs recommended to treat conditions without indica-
tion in the package insert or without data from scientific literature); replacement of obsolete
drugs (seven technologies), unavailability in the market (two technologies), stability/storage
(one technology). In nineteen cases that the scientific evidence was lacking, the arguments sup-
porting the decision were related to less efficacy or safety, along with others factors, however,
no scientific data were presented in the reports.
Of all assessments, clinical results extracted from the SUS database were used only in com-
paring the performance of interferon beta in the treatment of multiple sclerosis. Follow-up
data of around ten years of patients using interferon beta for the treatment of multiple sclerosis
in SUS demonstrated a statistically lower performance for intramuscular interferon beta as
compared to another interferon beta regarding effectiveness (relapses and death outcomes)
and treatment adherence.
The budget impact estimates supported 16 decisions (34%)—twelve for extended use
(increasing treatment period, changing lines or age range) of HIV/AIDS drugs, rheumatoid
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arthritis, multiple sclerosis, hepatitis A and hepatitis C and another four to an exclusion from
the SUS of technologies for HIV/AIDS, hepatitis C and malaria. Seven of these assessments
(15%) also used economic studies; being three cost-minimization studies, three cost-effective-
ness study, and one a cost-efficacy comparison. All these seven evaluations were related to the
requests for extension of use–six cases were for a change treatment line of drugs for rheuma-
toid arthritis, multiple sclerosis and AIDS, and one for the widening the age range for hepatitis
A vaccine.
In what concerns the public consultation, thirteen (27.6%) of the assessed technologies had
undergone this phase.
Decision factors for Conitec recommendations
Although various information was taken into account for Conitec deliberation, some criteria
were regarded as crucial for the decision-making (Tables 2 and 3). Concerning the disease, the
justification for unmet need (lack of an option in SUS) was fundamental for the use of the
drug fingolimod for multiple sclerosis (option for a failure of first and second line drugs) and
the hepatitis A vaccine (child population not covered by the vaccine).
Questions of adhesion, including dosage, route of administration and tolerability, impacted
in the evaluations for restriction of use of intramuscular interferon beta, expansion of use of




















































































































Check mark (“✓”) indicates the presence of the information and FD (factor decision) indicates the determinant criteria for the decision-making. BI: Budget impact; DF:
Decision factors; EA: Economic evaluation; EFC: Efficacy; EFT: Effectiveness; ID: International documents; NG: National guideline; SAF: Safety; UNM: Unmeet need.
aExtension of use—change in the therapeutic line
bExtension of use—wider age range
cExtension of use—increase in the treatment period.
https://doi.org/10.1371/journal.pone.0220131.t002
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didanosine, telaprevir and boceprevir from SUS list and exclusion of indications for the use of
injectable interferon alfa-2b in the treatment of hepatitis B.
In some delisted drugs, like telaprevir, boceprevir, stavudine, indinavir, and didanosine
obsolescence was perceived, and more efficient and safer drugs substituted them. The medica-
ment molgramostim, that was not marketed in Brazil due to its adverse events, was also
delisted. The obsolescence was also verified in the evaluation of some specific indications of fil-
grastim and epoetin alfa–situations of complications with the use of telaprevir and boceprevir.
With the exclusion of telaprevir and boceprevir, filgrastim and epoetin alfa lost their utility for
this indication, although they remained in SUS for other conditions.
For most technologies (42, 89%), the criterion of efficacy was essential for the Committee to
decide on extension of use (fourteen technologies), exclusion of specific indication for the use
of a technology (seventeen technologies), delisting from SUS (nine technologies), maintenance
in the health system and restriction of use (one technology each).
The fourteen drugs for which the efficacy was essential for decision of extension of use
were, related mainly to HIV/AIDS, rheumatoid arthritis and hepatitis C (5, 3 and 2 technolo-
gies, respectively). The other indications were: Gaucher disease, multiple sclerosis, breast neo-
plasm, and hepatitis A. In the cases of exclusion of indication (17 drugs), this criterion was
used majority for drugs for rheumatoid arthritis treatment (14 drugs). At last, the efficacy of
drugs for HIV/AIDS (5 drugs) and hepatitis C (2 drugs) was relevant for the de-listing deci-
sion-making. So, the relevance of this criterion was observed mainly for drugs related to HIV/
AIDS, rheumatoid arthritis and hepatitis, independent of the kind of recommendation.
Five technologies did not consider efficacy as a deciding factor for the recommendation.
These drugs were related to exclusion from the SUS (Three drugs for HIV/AIDS, cystic fibrosis
and various indications) and exclusion of indication (Two drugs for hepatitis C).
Data effectiveness from the scientific literature and the SUS data were relevant in seven
assessment for extension, exclusion, and restriction of use. To evaluate the comparison of the
efficacy of interferon beta, we used data from SUS that resulted in the restriction of
Table 3. Synthesis of the dimensions of analysis, criteria and decision factors according to Conitec recommenda-
tion reports.
Criteria Number of technologies that presented
information concerning the criteria
Number of technologies for which the










International documents 6 0
DIMENSION: SCIENTIFIC EVIDENCE




Budget impact 16 9
Economic evaluation 7 1
DIMENSION: SOCIAL PARTICIPATION
Public consultation 13 0
https://doi.org/10.1371/journal.pone.0220131.t003
Health technology reassessment in the Brazilian public health system
PLOS ONE | https://doi.org/10.1371/journal.pone.0220131 July 29, 2019 10 / 18
intramuscular beta interferon use. For the extension of the treatment period with sofosbuvir
and daclatasvir, real-world evidence obtained from European patient cirrhotic genotype 3 who
received treatment for hepatitis C during 24 weeks showing higher therapeutic successful
results rates were essential [22,23]. Due to this evidence, the most important therapeutic guides
in the world had started to recommend the extension of 24 weeks for patients’ cirrhotic geno-
type 3 treated with sofosbuvir in association or not to the ribavirin. In the case of hepatitis C,
telaprevir and boceprevir were withdraw from SUS due to the adoption of sofosbuvir, daclatas-
vir and simeprevir for the treatment of chronic C viral hepatitis, which was considered more
effective and safer according to the scientific literature. In the hepatitis vaccine assessment, the
effectiveness data in some countries had also been relevant for widening the age range. Exclu-
sion of interferon alfa-2b from the list of technologies for hepatitis B also considered effective-
ness data to be replaced by peginterferon alfa.
Information about safety supported the extension of the use of seven technologies, decisions
about the exclusion of nine technologies from SUS and exclusion of one specific indication.
The extensions of use referred to the change of line (raltegravir, abatacept, tocilizumab and to
dolutegravir), increase in the treatment period (sofosbuvir and daclatasvir) and the increase of
age group (raltegravir). In general, the delisted technologies were replaced by others, to main-
tain options in SUS, so, patients were not uncovered (artemether, fosamprenavir, didanosine,
adefovir, telaprevir, boceprevir, molgramostim, stavudine, and indinavir).
The costs were relevant for nine recommendations. The budget impact was considered a
decision factor in seven decisions about the expansion of use–raltegravir (two decisions), toci-
lizumab (two decisions), sofosbuvir, daclatasvir and hepatitis A vaccine–and in the exclusions
of telaprevir and boceprevir from SUS. The economic evaluation was taken into account to
support the extension of use of hepatitis A vacccine.
Other information were used to ratify the Committee’s recommendations, such as the
expansion of indications for registration with the ANVISA (Taliglucerase alfa and raltegravir),
lack of registration in Brazil (Pancrelipase and molgramostim), logistics of the program (Hepa-
titis A vaccine) and thermolability (Ritonavir).
Discussion
In order to analyze and describe the process of HTR performed by Conitec, 47 technologies
were selected. Several requests for reassessment originated in the Ministry of Health, Health
Departments and other institutions that comprise SUS, aimed at adapting the technologies
within the health system. There were a few private requests—a sixth as compared to the public,
and all were to change the treatment line for which the technology was already being offered
by the SUS. Therefore, the private requirements did not aim to fully analyze the interventions
within the system, but extend it use to a higher number of people.
There was only one decision, to the public demands, contrary to the request for widening
the age range for mammography as a method of breast cancer prevention because of the uncer-
tainty benefits to the population. For a private application, half of the deliberations was favor-
able and half-unfavorable to the extension of use.
Yuba et al. study evaluated the recommendations of all Conitec evaluations from 2012 to
2016 [24] and also noted that, proportionally, more assessments were issued as favorable when
the applicant was the public sector in detriment of the private sector. Thus, there is a tendency
that public requests obtain favorable recommendations. This phenomenon deserves thorough
scrutiny about its causes, which could be linked, among other hypotheses, to the source of
demand once the public claimants would be more aligned to the real needs of the health
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system or because it could occur a biased assessment to such requirements based on the rela-
tionship between plaintiff and appraiser.
Regarding the reason of the requests, the exclusion of some specific indication was the most
mentioned reason, followed by extension of the use of a technology and delisting from SUS.
These results reflect a worldwide trend in using HTR, which is not focusing on the total exclu-
sion of technology, but rather on refining clinical indications to optimize technology usage
and the resources allocation within a healthcare system. In the UK, The National Institute for
Health and Clinical Excellence is going towards this direction, having concluded that in prac-
tice, few technologies are prone to total disinvestment [14]. In New Zealand, due to the excel-
lent potential for reducing the prices of the medicines, the total exclusion becomes
unnecessary, and therefore rare [25].
Conversely, in France, the most active country in adopting the complete disinvestment
strategy, a comprehensive review of all 4,490 drugs listed between 2000 and 2004 was con-
ducted. As a result, 835 drugs were excluded from the national list (drugs surpassed by new
and more effective ones, unsafe medicines, and those no longer considered effective) and 617
drugs had a reduction of reimbursement rate from 65 to 35%. There were contestations by the
industry and between 2003 and 2006, a reevaluation of 723 drugs that were previously with-
drawn from the list confirmed that 525 of them were insufficient [25].
In Latin America, Agirrezabal et al. named some local disinvestment initiatives, although
most of them did not present a comprehensive description of the process used in finding, pri-
oritizing, evaluating, implementing, and the results of the disinvestment. Four studies referred
to Brazilian cases, and only one was considered as a potential disinvestment approach [26]. In
this case, Conitec assessed the intramuscular interferon beta-1a performance for multiple scle-
rosis. This analysis comprised two studies: a meta-analysis with mixed treatment comparison
and an assessment of the efficacy of the medicine in Brazilian patients (12,154 patients) using
the SUS database. The results demonstrated a statistically higher risk of treatment failure with
intramuscular interferon beta - 1a (exchange of treatment or relapse or death), pointing to the
inferiority of this medicine when compared to another interferon beta. Accordingly, there was
the decision of restriction of use in the treatment of multiple sclerosis, with the possibility of
maintenance of treatment for those who were already using it [27]. However, in October 2017,
the use restriction was revoked without published justification, after an appeal by the company
that holds the registration in Brazil [28].
Such results illustrate and emphasize the difficulty in removing technologies already avail-
able in the healthcare system, making it necessary to combine scientific data, in these cases,
more detailed and extensive, with the stakeholders’ interests. However, generating data that
contradict some practices is not always enough, since many physicians continue to administer
treatments proven ineffective and even harmful to patients [29].
In this context, policymakers may play a key role in regulating the use of such technologies,
and therefore should consider the adoption of active forms of disinvestment, not only those
aimed at total exclusion, but also the restriction treatment to subgroups, price or reimburse-
ment rate reductions, encouragement of generic prescribing [25].
Regarding the indication of requests, the vast majority of the technologies reviewed were
related to rheumatoid arthritis, HIV/AIDS, and hepatitis, which, along with oncology, repre-
sent the leading health topics for new adoption requests [30]. Considering the broad range of
pathologies and conditions covered by SUS, there is a greater focus in a few diseases, very likely
by the updates of the respective clinical protocols. However, many technologies are indicated
to a non-covered condition by the clinical protocols and therapeutic guidelines, which may
represent a gap in the selection process for reassessment. One example of this are the technolo-
gies for cancer treatment that are outside the scope of clinical protocols: 18 technologies were
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assessed during the period of this study, and none of them went through a review process.
Two other technologies available in the health system, before the existence of the Committee,
were reviewed–adjuvant chemotherapy, excluded for the treatment of squamous cell carci-
noma and mammography, which received an unfavorable recommendation to the widening
of the age range.
Thus, as highlighted above, reassessments were made based on demands, the vast majority
presented by the Ministry of Health itself and departments or organizations linked to SUS.
Demand-based assessment is limited by the fact that it does not systematize all technologies
that need to be adjusted in the face of new evidence (scientific or contextual) and those that
should be excluded because they are ineffective or unsafe.
Studies on disinvestment methodologies point out that the initial stages of selection and
prioritization are fundamental to generate greater transparency and enable all technologies to
be reviewed [12,31,32]. Some strategies can be applied in these stages, such as searching, moni-
toring and reviewing literature and public databases, consultation with clinical specialties
groups, reports of HTA agencies, consulting the health service of the healthcare system, evalua-
tion of variation in quantity (example 2, 3 or 5 years), amongst others [8,15,33].
However, setting the goal of the HTR program is required to decide on how to select and
prioritize technologies, as Sustainability in Health care by Allocating Resources Effectively
(SHARE) program in Australia advocates. In this case, "the aim of the SHARE Program was to
establish organization-wide, systematic, integrated, transparent, evidence-based systems and
processes for decision-making about disinvestment in the context of resource allocation at
Monash Health" [34].
Other initiatives that have been implemented in Australia sought to refine the indications
for resource allocation to ineffective or inappropriately applied health care practices, to subsi-
dize decision-related to ineffective drugs and vaccines in the Pharmaceutical Benefits Scheme
(PBS), also, to maximize the patients’ health and the supply sustainability. Some of these pro-
grams implemented in a local, regional and national level reported recommendations after
RTS, such as: disinvestment of assisted reproduction technologies (in vitro fertilization and
intracytoplasmic sperm injection), vitamin B12 and folate tests, discontinuation of public
funding of kyphoplasty and percutaneous vertebroplasty for vertebral compression, revisions
of colonoscopy items, surgical treatment for obesity, pulmonary artery catheterization, cathe-
terization in ophthalmology, and restriction in the rules for screening for cervical cancer
[35,36].
In Sweden, the nation-wide “Uncertainties and Disinvestment Project” was designed to
identify scientific uncertainties, to inform and support decision makers in prioritizing and
allocating resources within the health services. As a result, there was disinvestment of arthros-
copy in arthritis, a corticosteroid to lateral epicondylitis and, clinical replacement versus rou-
tine replacement of peripheral venous catheters. In the UK, NICE recommendations based
programmes aimed to inform about the financial aspect of resources utilization, safety, effec-
tiveness and health care quality process. Another initiative in the UK intended to reconfigured
services to provide more health gain at a reduced total cost [36].
Another point highlighted is the setting of deadlines for HTR, not observed in the Conitec
process. Citing the example of other countries a recent systematic review of the sustainability
programs and innovations have shown, in most of the studies, that the first evaluations were
conducted after two years of the technology implementation [17,37]. The definition of fixed
deadlines could eliminate the need for the selection of technologies for reassessment in the
cases of Conitec appraisal for its adoption [33]. To those that entered the system without Coni-
tec assessment, it would be necessary the adoption of standardized methodology with explicit
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criteria for screening the technologies to be reassessed to ensure periodic updates of all the list
of healthcare technologies [31,32].
The dimensions of analysis found in the recommendation reports were scientific evidence
on efficacy, effectiveness or safety, disease-related issues, issues related to the use of technology,
costs, and social participation. However, these dimensions were not included in all analysis,
and a standardized structure of the reports has not been observed.
To decision-making, the criteria of efficacy safety and use of the technology were the most
relevant for the set of evaluations. These data are in conformance to the primary concern of
the health systems from France, Australia, New Zealand, Canada and the UK, that is, to iden-
tify safety and efficacy problems that were not previously identified or underestimated in a
randomized clinical trial [25]. Besides, the HTR has been used in others countries to assess the
degree of adoption and usage of technology and, to provide the real costs and the use of health
technologies resources in real settings [38].
Another critical point to be mentioned was the lack of social participation through public
consultation in most of the decisions. Although the argument that some technologies can have
a fast-track appraisal process, the rules for this type of evaluation are not well defined. Thus,
such technologies were reassessed regardless of the stakeholders’ value and preference, which
may compromise the legitimacy and acceptability of the decision. In order to achieve greater
acceptance of decisions and to identify the potential impacts in the society, HTR process could
involve the politicians, clinicians, speciality societies, health system leaders, industry, and
patients [33]. In the United Kingdom, for example, the Technology Appraisal Committee
(TAC) which is responsible for decision making on disinvestment, has appointed members
from the National Health Service (NHS), patient and care organizations, academia, pharma-
ceutical and medical device industries. In Australia, deliberative methods were adopted to
develop stakeholder evidence-informed engagements. To achieve this, clinicians, consumers
and representative members of the community participate in the assessment [39].
The decision-making oriented by the results of the technology performance, although not
being observed as a regular practice by CONITEC, in other countries, some strategies have
been adopted in this sense. Negotiation for price reduction and reduction of reimbursement
rates has usually been implemented in countries such as Canada, France, Australia and New
Zealand after analyzing the results of technology performance [25,39]. In a study carried out in
Italy, the implementation of a product-specific monitoring registry was the possible determi-
nant associated with a higher price reduction of proposed price and negotiated price [40].
Managed entry agreements (MEAs) contractual agreements also have been used when
uncertainty regarding the clinical effectiveness, safety or resource use associated with a tech-
nology is high. This kind of agreement distributes the risk of uncertainty between the payers
and the manufacturer. In this case, additional further evidence generation is required [41]. Fol-
lowing this trend, the Brazilian Ministry of Health recently held the first international risk-
sharing workshop, thus beckoning to use performance data to adjust the price of technology
[42]. This new scenario reinforces the need to structure and strengthen the system to monitor
and evaluate the technologies available in the Brazilian health system, in order to evaluate
them in real conditions of the practical clinic and consequently, attribute the real value of such
technologies.
As limitations to the present study, we point out the reclassification of the decision types by
the authors as there is no definition of the term "reassessment" in SUS, and this may not reflect
the perspective of the technicians and managers who participate in the Conitec deliberations.
Moreover, the arguments described in the reports might not explicitly portray the justifications
for the decision-making presented during the Committee meeting.
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Conclusions
The reassessment process has appeared among other strategies for reducing the use of ineffec-
tive, less effective or unsafe practices and, consequently, to avoid a resources waste. The results
of Conitec six years of work presented initiatives with this goal. Although positive results were
obtained, this activity is not yet structured, with gaps regarding the selection phase and reas-
sessment of SUS list of technologies, since it has not been identified method and criteria for its
conduction.
Therefore, this study reinforces the need to prioritize structuring actions in within the SUS
that improve the management of technologies, both those recently incorporated and also these
adopted before the establishment of the Committee. Thus, it is suggested the implantation of a
monitoring program and HTR, with endorsed methodology and that it contemplates in deep-
ened way implementation questions (barriers and facilitators), stakeholder perspectives, and
scientific, social, ethical, and legal questions. Such actions need, inevitably, short-term time
and resources, but might add long-term gains in efficiency [43,44].
Finally, we expect that this study can contribute to the formulation of a systematic, trans-
parent, and objective process for a revision of the list of technologies offered by the Brazilian
Public Health System–SUS. Such process can be helpful in defining the "true" value of a given
technology in real conditions of use, contributing to better quality in the healthcare and sus-
tainability of the healthcare system.
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